Matinas BioPharma Holdings, Inc. 8K

Matinas BioPharma Holdings, Inc. announced it received an NYSE American notice of non-compliance with minimum stockholders’ equity listing standards, adding to prior deficiencies and placing it under a plan period through October 2, 2027 to regain compliance or risk delisting.

On August 31, 2026, Matinas BioPharma Holdings, Inc. received a notice from NYSE American LLC that it is not in compliance with the exchange’s continued listing standard in Section 1003(a)(i) of the NYSE American Company Guide, which requires at least $2.0 million in stockholders’ equity for companies with recent operating or net losses, as the company reported stockholders’ equity of $1.8 million as of June 30, 2026 and has incurred losses in each of its five most recent fiscal years; this notice is in addition to previously disclosed noncompliance with Sections 1003(a)(ii) and 1003(a)(iii), placing the company under the remedial procedures of Section 1009 pursuant to a previously accepted compliance plan that runs through October 2, 2027, during which its stock will remain listed with a .BC noncompliance indicator unless it regains full compliance or faces potential delisting proceedings.

Filing Facts

CIK

1582554

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-041577

Alert Tier

7